CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Davis |
Dr. John Laird |
Disease Team Therapy Development – Research |
Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia |
$3,728,384 |
| University of California, Davis |
Dr. Vicki Wheelock |
Disease Team Therapy Development – Research |
MSC engineered to produce BDNF for the treatment of Huntington’s disease |
$8,924,235 |
| StemCells, Inc. |
Dr. Nobuko Uchida |
Disease Team Therapy Development – Research |
Neural stem cell transplantation for chronic cervical spinal cord injury |
$0 |
| University of California, Davis |
Nancy E. Lane |
Disease Team Therapy Development – Research |
Treatment of non-traumatic osteonecrosis with endogenous Mesenchymal stem cells |
$18,227,898 |
| Salk Institute for Biological Studies |
Dr. David R Schubert |
Early Translational III |
Stem cell based small molecule therapy for Alzheimer’s disease |
$1,673,757 |
| City of Hope, Beckman Research Institute |
Dr. Stephen J Forman |
Early Translational III |
Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,215,447 |
| Gladstone Institutes, J. David |
Dr. Deepak Srivastava |
Early Translational III |
Direct Cardiac Reprogramming for Heart Regeneration |
$5,795,871 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Early Translational III |
Identifying Drugs for Alzheimer’s Disease with Human Neurons Made From Human IPS cells |
$1,774,420 |
| University of California, San Diego |
Dr Yang Xu |
Early Translational III |
Human ES cell based therapy of heart failure without allogenic immune rejection |
$1,857,600 |
| Stanford University |
Dr. Joseph C. Wu |
Early Translational III |
Heart Repair with Human Tissue Engineered Myocardium |
$4,395,080 |
| University of California, San Francisco |
Dr Morton Cowan |
Early Translational III |
Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID |
$3,862,367 |
| Stanford University |
Professor Helen M. Blau PhD |
Early Translational III |
Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients |
$1,825,283 |
| University of Southern California |
Dr. Toshio Miki |
Early Translational III |
Generation of hepatic cell from placental stem cell for congenital metabolic disorders |
$1,750,375 |
| Children’s Hospital of Orange County |
Philip Schwartz Ph.D. |
Early Translational III |
Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease |
$4,266,015 |
| University of California, San Francisco |
Dr. Holger F Willenbring |
Early Translational III |
Generation of safe and therapeutically effective human induced hepatocyte-like cells |
$1,544,170 |
| Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Early Translational III |
Direct reprogramming towards vascular progenitors for the treatment of ischemia |
$2,340,000 |
| University of California, San Diego |
Dr. Eric D. Adler |
Early Translational III |
Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease |
$1,701,575 |
| University of California, Davis |
Walter Douglas Boyd |
Early Translational III |
Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair |
$4,631,754 |
| Stanford University |
Dr. Bertha Chen |
Early Translational III |
Autologous iPSC Therapy for Urinary Incontinence |
$4,715,738 |
| University of California, San Diego |
Mark H Tuszynski |
Early Translational III |
Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury |
$4,600,447 |
| University of California, Davis |
Prof. Kyriacos A. Athanasiou Ph.D |
Early Translational III |
Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells |
$1,735,703 |
| University of California, Irvine |
Craig Michael Walsh |
Early Translational III |
Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells |
$4,535,005 |
| Scripps Research Institute |
Peter G. Schultz |
Early Translational III |
Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis |
$2,559,333 |
| University of California, San Francisco |
Dr. Arnold Kriegstein MD, PhD |
Early Translational III |
Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury |
$1,623,251 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Early Translational III |
Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons |
$1,532,323 |
| University of California, Santa Cruz |
Dr. David Haussler |
Training Grant I-3 |
Training Program in Systems Biology of Stem Cells |
$1,133,701 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg |
Training Grant I-3 |
UCSB Stem Cell Biology Training Program |
$975,334 |
| Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Training Grant I-3 |
Training in the Biology of Human Enbryonic Stem Cells and Emerging Technologies |
$1,261,333 |
| California Institute of Technology |
Paul H. Patterson |
Training Grant I-2 |
Training in Stem Cell Biology at CIT |
$1,817,214 |
| Children’s Hospital of Los Angeles |
Dr. Donald B. Kohn |
Training Grant I-2 |
Training Grant 1 |
$2,173,872 |
| Sanford Burnham Prebys Medical Discovery Institute |
Mark Mercola |
Training Grant I-2 |
Burnham Institute CIRM Stem Cell Training Grant (Type II) |
$1,061,865 |
| Gladstone Institutes, J. David |
Dr. Robert W Mahley |
Training Grant I-2 |
Gladstone CIRM Scholar Program |
$2,192,073 |
| Scripps Research Institute |
Peter G. Schultz |
Training Grant I-2 |
Training Grant I |
$1,021,395 |
| University of California, Davis |
Dr. Frederick J Meyers MD |
Training Grant I-1 |
Stem Cell Research Training Grant |
$1,780,859 |
| Stanford University |
Dr. Katja Weinacht |
Preclinical Stage Projects |
Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells |
$12,999,871 |
| EVADE Therapeutics |
Sonja Schrepfer |
Preclinical Stage Projects |
Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes |
$12,480,000 |
| University of Southern California |
Charles Murry |
Preclinical Stage Projects |
Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. |
$7,499,998 |
| University of California, Los Angeles |
Dr. Lili Yang |
Preclinical Stage Projects |
Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis |
$7,499,996 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |